Zhejiang Hisun Pharmaceutical Co., Ltd.SSE: 600267

Report for Q3 2025

Oct 28, 2025 · Issued by Zhejiang Hisun Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Oct 28, 2025

On 6ix: 6ix.com/news/report-for-q3-2025-144

Report for Q3 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Zhejiang Hisun Pharmaceutical Co., Ltd. on 6ix

Earlier from Zhejiang Hisun Pharmaceutical

Announcement on Convening the Q3 2025 Performance BriefingOct 25, 2025
Announcement on the Revocation of the "GMP Non-Compliance Statement" for the Taizhou Factory by the European UnionOct 20, 2025
Announcement on the Company’s Products Obtaining the Self-GRAS Certification from the United StatesOct 10, 2025
Announcement on Resolutions of the 7th Meeting of the 10th Board of DirectorsSep 17, 2025
Announcement on the Obtainment of CEP Certificate for Tigecycline Active Pharmaceutical IngredientSep 13, 2025

Later from Zhejiang Hisun Pharmaceutical

Announcement on Voluntary Disclosure of Prospective Winning in the National Centralized Drug ProcurementOct 30, 2025
Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025Nov 6, 2025
Announcement on Public Transfer of 100% Equity in the Wholly-owned Subsidiary Zhejiang Pharmaceutical Industry Corp., Ltd.Nov 12, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025Nov 13, 2025
Announcement on Resolutions of the 9th Meeting of the 10th Board of DirectorsNov 20, 2025

All Zhejiang Hisun Pharmaceutical news releases

Follow Zhejiang Hisun Pharmaceutical into a list and get an email when it puts out news.

Follow Zhejiang Hisun Pharmaceutical